Expression Profiles of circRNAs and Identification of hsa_circ_0007608 and hsa_circ_0064656 as Potential Biomarkers for COPD-PH Patients

References

• Ding X, Lin Q, Zhao J, et al. Synonymous mutations in TLR2 and TLR9 genes decrease COPD susceptibility in the Chinese Han population. Pulmonology. 2022;S2531-0437(22):220. doi:10.1016/j.pulmoe.2022.09.010
   Google Scholar
• Ma C, Liao K, Wang J, et al. L-Arginine, as an essential amino acid, is a potential substitute for treating COPD via regulation of ROS/NLRP3/NF-κB signaling pathway. Cell Biosci. 2023;13:152. doi:10.1186/s13578-023-00994-9
   PubMed Web of Science ®Google Scholar
• Blanco I, Tura-Ceide O, Peinado VI, et al. Updated Perspectives on Pulmonary Hypertension in COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1315–1324. doi:10.2147/COPD.S211841
   PubMed Web of Science ®Google Scholar
• Vizza CD, Hoeper MM, Huscher D, et al. Pulmonary Hypertension in Patients With COPD: results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Chest. 2021;160(2):678–689.
   PubMed Web of Science ®Google Scholar
• Boucly A, Savale L, Jaïs X, et al. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2021;204(7):842–854. doi:10.1164/rccm.202009-3698OC
   PubMed Web of Science ®Google Scholar
• Yu X, Qin W, Lin X, et al. Synergizing the enhanced RIME with fuzzy K-nearest neighbor for diagnose of pulmonary hypertension. Comput Biol Med. 2023;165:107408. doi:10.1016/j.compbiomed.2023.107408
   PubMed Web of Science ®Google Scholar
• Zheng R, Xu T, Wang X, et al. Stem cell therapy in pulmonary hypertension: current practice and future opportunities. Eur Respir Rev. 2023;32(169):230112. doi:10.1183/16000617.0112-2023
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–691.
   PubMed Web of Science ®Google Scholar
• Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–388. doi:10.1038/nature11993
   PubMed Web of Science ®Google Scholar
• Luo H, Xiao T, Sun X, et al. The regulation of circRNA_kif26b on alveolar epithelial cell senescence via miR-346-3p is involved in microplastics-induced lung injuries. Sci Total Environ. 2023;882:163512. doi:10.1016/j.scitotenv.2023.163512
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhu J, Zhou H, et al. The involvement of copper, circular RNAs, and inflammatory cytokines in chronic respiratory disease. Chemosphere. 2022;303(Pt 2):135005. doi:10.1016/j.chemosphere.2022.135005
   PubMedGoogle Scholar
• Xia H, Wu Y, Zhao J, et al. N6-Methyladenosine-modified circSAV1 triggers ferroptosis in COPD through recruiting YTHDF1 to facilitate the translation of IREB2. Cell Death Differ. 2023;30(5):1293–1304. doi:10.1038/s41418-023-01138-9
   PubMed Web of Science ®Google Scholar
• Hong L, Ma X, Liu J, et al. Circular RNA-HIPK3 regulates human pulmonary artery endothelial cells function and vessel growth by regulating microRNA-328-3p/STAT3 axis. Pulm Circ. 2021;11(2):20458940211000234. doi:10.1177/20458940211000234
   Web of Science ®Google Scholar
• Jin X, Xu Y, Guo M, et al. hsa_circNFXL1_009 modulates apoptosis, proliferation, migration, and potassium channel activation in pulmonary hypertension. Mol Ther Nucleic Acids. 2020;23:1007–1019. doi:10.1016/j.omtn.2020.09.029
   PubMedGoogle Scholar
• Yin L, Tang Y, Yuan Y. An Overview of the Advances in Research on the Molecular Function and Specific Role of Circular RNA in Cardiovascular Diseases. Biomed Res Int. 2022;2022:5154122. doi:10.1155/2022/5154122
   PubMed Web of Science ®Google Scholar
• Pan S, Chen Y, Yan Y, et al. The emerging roles and mechanisms of exosomal non-coding RNAs in the mutual regulation between adipose tissue and other related tissues in obesity and metabolic diseases. Front Endocrinol (Lausanne). 2022;13:975334. doi:10.3389/fendo.2022.975334
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang C, Lu X, et al. Transcriptome sequencing of hepatocellular carcinoma uncovers multiple types of dysregulated ncRNAs. Front Oncol. 2022;12:927524. doi:10.3389/fonc.2022.927524
   PubMed Web of Science ®Google Scholar
• Zheng H, Hua J, Li H, et al. Comprehensive analysis of the expression of N6-methyladenosine RNA methylation regulators in pulmonary artery hypertension. Front Genet. 2022;13:974740. doi:10.3389/fgene.2022.974740
   PubMed Web of Science ®Google Scholar
• Han X, Li C, Yang P, et al. Potential mechanisms of Qili Qiangxin capsule to prevent pulmonary arterial hypertension based on network pharmacology analysis in a rat model. Ann Transl Med. 2022;10(8):453. doi:10.21037/atm-22-901
   PubMed Web of Science ®Google Scholar
• Wang J, Uddin MN, Wang R, et al. Comprehensive analysis and validation of novel immune and vascular remodeling related genes signature associated with drug interactions in pulmonary arterial hypertension. Front Genet. 2022;13:922213. doi:10.3389/fgene.2022.922213
   PubMed Web of Science ®Google Scholar
• Wei RQ, Zhang WM, Liang Z, et al. Identification of Signal Pathways and Hub Genes of Pulmonary Arterial Hypertension by Bioinformatic Analysis. Can Respir J. 2022;2022:1394088. doi:10.1155/2022/1394088
   PubMed Web of Science ®Google Scholar
• Wang RR, Yuan TY, Chen D, et al. Dan-Shen-Yin Granules Prevent Hypoxia-Induced Pulmonary Hypertension via STAT3/HIF-1α/VEGF and FAK/AKT Signaling Pathways. Front Pharmacol. 2022;13:844400. doi:10.3389/fphar.2022.844400
   PubMed Web of Science ®Google Scholar
• Tang S, Liu Y, Liu B. Integrated bioinformatics analysis reveals marker genes and immune infiltration for pulmonary arterial hypertension. Sci Rep. 2022;12(1):10154. doi:10.1038/s41598-022-14307-6
   PubMed Web of Science ®Google Scholar
• Tu J, Jin J, Chen X, et al. Altered Cellular Immunity and Differentially Expressed Immune-Related Genes in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Front Immunol. 2022;13:868983. doi:10.3389/fimmu.2022.868983
   PubMed Web of Science ®Google Scholar
• Lin W, Tang Y, Zhang M, et al. Integrated Bioinformatic Analysis Reveals TXNRD1 as a Novel Biomarker and Potential Therapeutic Target in Idiopathic Pulmonary Arterial Hypertension. Front Med. 2022;9:894584. doi:10.3389/fmed.2022.894584
   Web of Science ®Google Scholar
• Wang S, Liu Y, Wang Q, et al. Utilizing Network Pharmacology and Molecular Docking Integrated Surface Plasmon Resonance Technology to Investigate the Potential Targets and Mechanisms of Tripterygium wilfordii against Pulmonary Artery Hypertension. Evid Based Complement Alternat Med. 2022;2022:9862733. doi:10.1155/2022/9862733
   PubMed Web of Science ®Google Scholar
• Wei R, Chen L, Li P, et al. IL-13 alleviates idiopathic pulmonary hypertension by inhibiting the proliferation of pulmonary artery smooth muscle cells and regulating macrophage infiltration. Am J Transl Res. 2022;14(7):4573–4590.
   PubMed Web of Science ®Google Scholar
• Xu SL, Deng YS, Liu J, et al. Regulation of circular RNAs act as ceRNA in a hypoxic pulmonary hypertension rat model. Genomics. 2021;113(1 Pt 1):11–19. doi:10.1016/j.ygeno.2020.11.021
   PubMed Web of Science ®Google Scholar
• Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53(1):1801887. doi:10.1183/13993003.01887-2018
   PubMed Web of Science ®Google Scholar
• Woo KV, Shen IY, Weinheimer CJ, et al. Endothelial FGF signaling is protective in hypoxia-induced pulmonary hypertension. J Clin Invest. 2021;131(17):e141467. doi:10.1172/JCI141467
   PubMed Web of Science ®Google Scholar
• Gallardo-Vara E, Ntokou A, Dave JM, et al. Vascular pathobiology of pulmonary hypertension. J Heart Lung Transplant. 2023;42(5):544–552. doi:10.1016/j.healun.2022.12.012
   PubMed Web of Science ®Google Scholar
• Xu WJ, Wu Q, He WN, et al. Interleukin-6 and pulmonary hypertension: from physiopathology to therapy. Front Immunol. 2023;14:1181987. doi:10.3389/fimmu.2023.1181987
   PubMed Web of Science ®Google Scholar
• Kucherenko MM, Sang P, Yao J, et al. Elastin stabilization prevents impaired biomechanics in human pulmonary arteries and pulmonary hypertension in rats with left heart disease. Nat Commun. 2023;14(1):4416. doi:10.1038/s41467-023-39934-z
   PubMedGoogle Scholar
• Chelladurai P, Seeger W, Pullamsetti SS. Matrix metalloproteinases and their inhibitors in pulmonary hypertension. Eur Respir J. 2012;40(3):766–782. doi:10.1183/09031936.00209911
   PubMed Web of Science ®Google Scholar
• Guo X, Meng Y, Wang Y, et al. Mice lacking 1,4,5-triphosphate inositol type III receptor demonstrate inhibition of hypoxic pulmonary hypertension. Biochem Biophys Res Commun. 2022;629:165–170. doi:10.1016/j.bbrc.2022.09.036
   PubMed Web of Science ®Google Scholar
• Gabani M, Liu J, Ait-Aissa K, et al. MiR-204 regulates type 1 IP3R to control vascular smooth muscle cell contractility and blood pressure. Cell Calcium. 2019;80:18–24. doi:10.1016/j.ceca.2019.03.006
   PubMed Web of Science ®Google Scholar
• Balistrieri A, Makino A, Yuan JX. Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca2+ signaling. Physiol Rev. 2023;103(3):1827–1897. doi:10.1152/physrev.00030.2021
   PubMed Web of Science ®Google Scholar
• Pérez L, Muñoz-Durango N, Riedel CA, et al. Endothelial-to-mesenchymal transition: cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine Growth Factor Rev. 2017;33:41–54. doi:10.1016/j.cytogfr.2016.09.002
   PubMed Web of Science ®Google Scholar
• Silva GF, da Silva JS, de Alencar AKN, et al. Novel p38 Mitogen-Activated Protein Kinase Inhibitor Reverses Hypoxia-Induced Pulmonary Arterial Hypertension in Rats. Pharmaceuticals. 2022;15(7):900. doi:10.3390/ph15070900
   Web of Science ®Google Scholar
• Pugliese SC, Poth JM, Fini MA, et al. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am J Physiol Lung Cell Mol Physiol. 2015;308(3):L229–L252. doi:10.1152/ajplung.00238.2014
   PubMed Web of Science ®Google Scholar
• Maleszewska M, Moonen JR, Huijkman N, et al. IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner. Immunobiology. 2013;218(4):443–454. doi:10.1016/j.imbio.2012.05.026
   PubMed Web of Science ®Google Scholar
• Chen PY, Qin L, Baeyens N, et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest. 2015;125(12):4514–4528. doi:10.1172/JCI82719
   PubMed Web of Science ®Google Scholar
• Adjuto-Saccone M, Soubeyran P, Garcia J, et al. TNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. Cell Death Dis. 2021;12(7):649. doi:10.1038/s41419-021-03920-4
   PubMed Web of Science ®Google Scholar
• Jang AJ, Chang SS, Park C, et al. PPARγ increases HUWE1 to attenuate NF-κB/p65 and sickle cell disease with pulmonary hypertension. Blood Adv. 2021;5(2):399–413. doi:10.1182/bloodadvances.2020002754
   PubMed Web of Science ®Google Scholar
• Iranmehr A, Stobdan T, Zhou D, et al. Novel insight into the genetic basis of high-altitude pulmonary hypertension in Kyrgyz highlanders. Eur J Hum Genet. 2019;27(1):150–159. doi:10.1038/s41431-018-0270-8
   PubMed Web of Science ®Google Scholar
• Kumar R, Mickael C, Kassa B, et al. Interstitial macrophage-derived thrombospondin-1 contributes to hypoxia-induced pulmonary hypertension. Cardiovasc Res. 2020;116(12):2021–2030. doi:10.1093/cvr/cvz304
   PubMed Web of Science ®Google Scholar
• Moll M, Christmann RB, Zhang Y, et al. Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. J Scleroderma Relat Disord. 2018;3(3):242–248. doi:10.1177/2397198318764780
   PubMed Web of Science ®Google Scholar